EC approves Vertex’s Casgevy for sickle cell disease treatment
Betsy Goodfellow | February 13, 2024 | News story | Medical Communications | Casgevy, European Commission, Haematology, Vertex pharmaceuticals, sickle cell disease
Vertex Pharmaceuticals has announced that the European Commission (EC) has granted conditional marketing authorisation to Casgevy (exagamglogene autotemcel), a CRISPR/Cas9 gene-edited therapy.
Casgevy is approved for the treatment of patients over the age of 12 with severe sickle cell disease (SCD) characterized by recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT), in patients for whom haematopoietic stem cell (HSC) transplantation is appropriate and when a human leukocyte antigen matched related HSC donor is not available.
The drug is now the only genetic therapy available for SCD and TDT patients in the EU following this approval.
Reshma Kewalramani MD, chief executive officer and president of Vertex, commented: “With this approval, Casgevy is now approved for SCD and TDT in multiple geographies making tens of thousands of patients eligible for this potentially transformative therapy. Now our goal shifts to translating these approvals into real-world patient benefit and ensuring access and reimbursement across the globe.”
Franco Locatelli MD PhD, principal investigator in the CLIMB-111 and CLIMB-121 studies, professor of paediatrics at the Catholic University of the Sacred Heart, Rome, Italy, and director of the Department of Pediatric Hematology and Oncology at the Bambino Gesù Children’s Hospital, Italy, added: “SCD and TDT are debilitating, life-shortening diseases associated with significant burden on patients, families and health care systems. Casgevy offers the potential of a functional cure, and it will be important to offer this therapeutic option to eligible patients as soon as possible.”
The company is already working with the relevant health authorities to ensure the drug is available to those who need it as quickly as possible.
Betsy Goodfellow
Related Content
European Commission approves HIV prevention injection
The European Commission (EC) has granted marketing authorisation for Gilead Science’s Yeytuo (lenacapavir), the first …
Sanofi’s Sarclisa gains EU approval for multiple myeloma treatment
Sanofi has received approval from the European Commission for the use of Sarclisa (isatuximab) in …
Biocon Biologics gains EU approval for bone health therapies
Biocon Biologics has announced that the European Commission has granted marketing authorisation for its denosumab …
